Article
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2012
Weickhardt Andrew J, Price Tim J, Chong Geoff, Gebski Val, Pavlakis Nick, Johns Terrance G, Azad Arun, Skrinos Effie, Fluck Kate, Dobrovic Alexander, Salemi Renato, Scott Andrew M, Mariadason John M, Tebbutt Niall C
Abstract excerpt
PURPOSE: This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: The activity and mechanism of action of the combination of cetuximab plus erlotinib were investigated in vitro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.